These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17621563)

  • 1. The oncology impact of highly active antiretroviral therapy.
    Schlichemeyer R; Chambers C; Gill MJ
    J Oncol Pharm Pract; 2007 Mar; 13(1):17-25. PubMed ID: 17621563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
    Gingues S; Gill MJ
    HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
    Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
    Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric HIV costs across three treatment eras from 1986 to 2007.
    Wilson LS; Basu R; Christenson M; Hensic L; Paoli C; Wara D; Moskowitz JT
    Pediatrics; 2010 Sep; 126(3):e541-9. PubMed ID: 20696721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV infection and cancer in the era of highly active antiretroviral therapy (Review).
    Barbaro G; Barbarini G
    Oncol Rep; 2007 May; 17(5):1121-6. PubMed ID: 17390054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ocular manifestations in patients with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy].
    Mesarić B; Lisić M; Kniewald T; Ugrinović N; Begovac J
    Lijec Vjesn; 2005; 127(5-6):123-8. PubMed ID: 16281473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
    Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
    J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
    Herida M; Mary-Krause M; Kaphan R; Cadranel J; Poizot-Martin I; Rabaud C; Plaisance N; Tissot-Dupont H; Boue F; Lang JM; Costagliola D
    J Clin Oncol; 2003 Sep; 21(18):3447-53. PubMed ID: 12972519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.
    Klibanov OM; Clark-Vetri R
    Pharmacotherapy; 2007 Jan; 27(1):122-36. PubMed ID: 17192166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).
    Kapogiannis BG; Soe MM; Nesheim SR; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2008 May; 121(5):e1229-39. PubMed ID: 18450865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of transplantation in HIV patients during the HAART era.
    Pelletier SJ; Norman SP; Christensen LL; Stock PG; Port FK; Merion RM
    Clin Transpl; 2004; ():63-82. PubMed ID: 16704139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian Register for HIV Infection in Children.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Lisi C; Giaquinto C; Rampon O; Gattinara GC; De Marco G; Osimani P; Manzionna M; Miniaci A; Pintor C; Rosso R; Esposito S; Viganò A; Dodi I; Maccabruni A; Fundarò C; de Martino M;
    J Clin Oncol; 2007 Jan; 25(1):97-101. PubMed ID: 17194910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing pattern of primary cerebral lymphoma in the highly active antiretroviral therapy era.
    Cingolani A; Fratino L; Scoppettuolo G; Antinori A
    J Neurovirol; 2005; 11 Suppl 3():38-44. PubMed ID: 16540454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-related malignancies pre- and post-highly active antiretroviral therapy: experiences in an inner city tertiary referral centre.
    Kiely B; O'Flaherty J; Surah S; Kieran J; O'Donnell D; Bergin C; Mulcahy F
    Int J STD AIDS; 2010 May; 21(5):332-6. PubMed ID: 20498102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma.
    Bower M; Powles T; Nelson M; Mandalia S; Gazzard B; Stebbing J
    J Natl Cancer Inst; 2006 Aug; 98(15):1088-91. PubMed ID: 16882946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prophylaxis against adverse effects of chemotherapy for HIV positive patients].
    Bentata M
    Bull Cancer; 2003 May; 90(5):427-34. PubMed ID: 12850766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.